Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out the advertisement of prescriptions for injectable weight-loss drugs without ...

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

SGLT-2 inhibitors and GLP-1 receptor agonists are linked to a reduced risk of COPD exacerbations in patients with type 2 ...

A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol consumption.

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Ozempic may help reduce alcohol cravings, according to a new study. But you shouldn't use them to help curb drinking habits ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb. 3 in ...

The findings of this study provide initial prospective evidence that low-dose semaglutide can reduce craving and some drinking outcomes, justifying larger clinical trials to evaluate glucagon-like ...